Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · Real-Time Price · USD
0.3250
-0.0257 (-7.33%)
At close: Jun 26, 2025, 4:00 PM
0.3412
+0.0162 (4.98%)
Pre-market: Jun 27, 2025, 7:26 AM EDT
Mersana Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 102.29 | 107.75 | 174.56 | 128.89 | 177.95 | 255.09 | Upgrade
|
Short-Term Investments | - | 26.87 | 34.52 | 151.83 | - | - | Upgrade
|
Cash & Short-Term Investments | 102.29 | 134.62 | 209.08 | 280.71 | 177.95 | 255.09 | Upgrade
|
Cash Growth | -44.15% | -35.61% | -25.52% | 57.75% | -30.24% | 155.63% | Upgrade
|
Receivables | - | - | - | 30 | - | - | Upgrade
|
Prepaid Expenses | 3.58 | 2.28 | 4.97 | 8.51 | 10.95 | 3.49 | Upgrade
|
Total Current Assets | 106.19 | 136.9 | 214.06 | 319.22 | 188.9 | 258.58 | Upgrade
|
Property, Plant & Equipment | 5.63 | 6.78 | 11.53 | 14.46 | 14.86 | 12.67 | Upgrade
|
Other Long-Term Assets | 0.66 | 0.98 | 0.48 | 0.66 | 2.36 | 2.15 | Upgrade
|
Total Assets | 112.47 | 144.66 | 226.06 | 334.34 | 206.11 | 273.4 | Upgrade
|
Accounts Payable | 4.37 | 4.33 | 7.32 | 13.95 | 12.32 | 8.34 | Upgrade
|
Accrued Expenses | 12.97 | 18.96 | 20.85 | 43.18 | 28.72 | 16.15 | Upgrade
|
Current Portion of Long-Term Debt | 12.5 | 12.5 | 2.08 | - | - | - | Upgrade
|
Current Portion of Leases | 3.96 | 3.9 | 3.4 | 3.04 | 2.54 | 1.53 | Upgrade
|
Current Unearned Revenue | 23.72 | 22.17 | 28.15 | 30.61 | 3.94 | 3.99 | Upgrade
|
Other Current Liabilities | 0.64 | 0.59 | 1.84 | 0.75 | - | - | Upgrade
|
Total Current Liabilities | 58.16 | 62.46 | 63.64 | 91.53 | 47.52 | 30 | Upgrade
|
Long-Term Debt | 7.9 | 10.95 | 23.15 | 24.93 | 24.63 | 4.98 | Upgrade
|
Long-Term Leases | 0.26 | 1.3 | 5.2 | 8.78 | 11.7 | 10.33 | Upgrade
|
Long-Term Unearned Revenue | 77.02 | 79.46 | 97.17 | 117.04 | - | - | Upgrade
|
Other Long-Term Liabilities | - | - | 0 | - | 0.53 | - | Upgrade
|
Total Liabilities | 143.34 | 154.17 | 189.16 | 242.28 | 84.37 | 45.31 | Upgrade
|
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
Additional Paid-In Capital | 888.8 | 886.02 | 863.24 | 746.89 | 572.21 | 508.5 | Upgrade
|
Retained Earnings | -919.68 | -895.55 | -826.36 | -654.69 | -450.48 | -280.42 | Upgrade
|
Comprehensive Income & Other | - | 0.01 | 0.01 | -0.15 | - | - | Upgrade
|
Total Common Equity | -30.87 | -9.51 | 36.9 | 92.06 | 121.74 | 228.09 | Upgrade
|
Shareholders' Equity | -30.87 | -9.51 | 36.9 | 92.06 | 121.74 | 228.09 | Upgrade
|
Total Liabilities & Equity | 112.47 | 144.66 | 226.06 | 334.34 | 206.11 | 273.4 | Upgrade
|
Total Debt | 24.62 | 28.65 | 33.83 | 36.75 | 38.86 | 16.84 | Upgrade
|
Net Cash (Debt) | 77.66 | 105.97 | 175.25 | 243.97 | 139.08 | 238.26 | Upgrade
|
Net Cash Growth | -48.03% | -39.53% | -28.17% | 75.41% | -41.62% | 159.92% | Upgrade
|
Net Cash Per Share | 0.63 | 0.86 | 1.51 | 2.60 | 1.97 | 3.88 | Upgrade
|
Filing Date Shares Outstanding | 124.63 | 124.63 | 121.3 | 108.03 | 83.39 | 69.04 | Upgrade
|
Total Common Shares Outstanding | 124.63 | 115.65 | 120.71 | 105.14 | 73.71 | 68.84 | Upgrade
|
Working Capital | 48.03 | 74.45 | 150.42 | 227.69 | 141.38 | 228.58 | Upgrade
|
Book Value Per Share | -0.25 | -0.08 | 0.31 | 0.88 | 1.65 | 3.31 | Upgrade
|
Tangible Book Value | -30.87 | -9.51 | 36.9 | 92.06 | 121.74 | 228.09 | Upgrade
|
Tangible Book Value Per Share | -0.25 | -0.08 | 0.31 | 0.88 | 1.65 | 3.31 | Upgrade
|
Machinery | - | 10.29 | 10.7 | 9.78 | 7.74 | 7.48 | Upgrade
|
Leasehold Improvements | - | 2.21 | 2.21 | 1.94 | 1.91 | 1.89 | Upgrade
|
Updated May 15, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.